{"about":{"non_affiliation":"Code with Papers and Syntology are not affiliated with, endorsed by, or sponsored by Papers with Code, Meta, or the pwc-archive mirror.","site":"https://codewithpapers.app","licence":"CC BY-SA 4.0","licence_url":"https://creativecommons.org/licenses/by-sa/4.0/legalcode","attribution":"https://codewithpapers.app/attribution","modified":"archive material modified by Syntology; see the attribution page","syntology":{"site":"https://syntology.ai","developers":"https://syntology.ai/developers","mcp":{"server":"https://syntology.ai/mcp","transport":"streamable-http","server_card":"https://syntology.ai/.well-known/mcp/server-card.json","auth":{"type":"trial token, no account","trial_token":"https://syntology.ai/api/oauth/trial/token","method":"POST","docs":"https://syntology.ai/developers"}},"have":"https://syntology.ai/api/graph/have?x=<method, arXiv id or title> (free, answers coverage only)","paper_base":"https://syntology.ai/paper/","atlas_base":"https://app.syntology.ai/?focus="},"machine_readable":[{"url":"https://codewithpapers.app/llms.txt","what":"the machine catalog: every machine-readable file, counted"},{"url":"https://codewithpapers.app/index/manifest.json","what":"paper-to-code index by arXiv id, with Syntology's counts"},{"url":"https://codewithpapers.app/search/manifest.json","what":"site search index (titles, authors) and its files"},{"url":"https://codewithpapers.app/download","what":"bulk files: Syntology's layer, described there"},{"url":"https://codewithpapers.app/build_manifest.json","what":"the build record: inputs, counts, exclusions, probes"}]},"url":"/paper/blocking-of-the-cd80-86-axis-as-a-therapeutic","title":"Blocking of the CD80/86 axis as a therapeutic approach to prevent progression to more severe forms of COVID-19","arxiv_id":"2005.10055","date":"2020-05-20","proceeding":null,"authors":["Antonio Julià","Irene Bonafonte","Antonio Gómez","María López-Lasanta","Mireia López-Corbeto","Sergio H. Martínez-Mateu","Jordi Lladós","Iván Rodríguez-Nunez","Richard M. Myers","Sara Marsal"],"abstract":"In its more severe forms, COVID-19 progresses towards an excessive immune response, leading to the systemic overexpression of proinflammatory cytokines like IL6, mostly from the infected lungs. This cytokine storm can cause multiple organ damage and death. Consequently, there is a pressing need to identify therapies to treat and prevent severe symptoms during COVID-19. Based on previous clinical evidence, we hypothesized that inhibiting T cell co-stimulation by blocking CD80/86 could be an effective therapeutic strategy against progression to severe proinflammatory states. To support this hypothesis, we performed an analysis integrating blood transcriptional data we generated from rheumatoid arthritis patients treated with abatacept -- a CD80/86 co-stimulation inhibitor -- with the pathological features associated with COVID-19, particularly in its more severe forms. We have found that many of the biological processes that have been consistently associated with COVID-19 pathology are reversed by CD80/86 co-stimulation inhibition, including the downregulation of IL6 production. Also, analysis of previous transcriptional data from blood of SARS-CoV-infected patients showed that the response to abatacept has a very high level of antagonism to that elicited by COVID-19. Finally, analyzing a recent single cell RNA-seq dataset from bronchoalveolar lavage fluid cells from COVID-19 patients, we found a significant correlation along the main elements of the C80/86 axis: CD86+/80+ antigen presenting cells, activated CD4+ T cells and IL6 production. Our in-silico study provides additional support to the hypothesis that blocking of the CD80/CD86 signaling axis may be protective of the excessive proinflammatory state associated with COVID-19 in the lungs.","url_abs":"https://arxiv.org/abs/2005.10055v1","url_pdf":"https://arxiv.org/pdf/2005.10055v1.pdf","source":{"archive":"pwc-archive (Hugging Face), CC BY-SA 4.0","snapshot":"2025-07-28","licence_url":"https://creativecommons.org/licenses/by-sa/4.0/legalcode","row_kind":"abstracts"},"code_links":[{"paper_slug":"blocking-of-the-cd80-86-axis-as-a-therapeutic","repo_url":"https://github.com/Rheumatology-Research-Group/COVID-19_Abatacept","is_official":0,"mentioned_in_paper":0,"mentioned_in_github":1,"framework":"none","reach":null}],"tasks":[{"task_slug":"blocking","task_name":"Blocking"}],"methods":[],"datasets_introduced":[],"methods_introduced":[],"results":[],"syntology":{"syntology_url":null,"atlas_url":null,"mcp":null,"developers":"https://syntology.ai/developers","held":null,"reason":"arxiv_id_not_in_atlas","checked_against":{"atlas_ids":549449,"atlas_ids_sha256":"afd72399dafd9906e9062927f70655952385a3d75488558e1f0484e950ab09b7","read_at":"2026-10-05T01:46:21Z"},"by_repo":[{"repo":"Rheumatology-Research-Group/COVID-19_Abatacept","kind":"listed","samples":0,"ran":0,"instrument":0,"unverified":0}],"by_repo_is":"one row per repository in the archive's code links, Syntology's graph links or the samples; samples 0 means no sample is linked to this paper, a statement about Syntology's coverage, not about the repository: with harvested_for_other_papers present, Syntology harvested the repository for that many other papers, and without it, Syntology harvested nothing from it; placed_by_identical_code counts samples whose link records no repository, placed here because identical code was harvested from this repository for another paper; ran counts executions on a synthesized input and instrument counts failures of Syntology's instrument, not of the code"},"code_links_note":null,"arxiv_metadata":null,"syntology_extracted_results":null,"record_sha256":"26cb0f32369a928f6a6ed51d2fe39e6d647f6e0a0d801ac55038757484d7919f","record_changed_at":"2026-09-28","record_changed_at_basis":"first_hashed"}